• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012 Product Image

H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012

  • Published: December 2012
  • 204 pages
  • Global Markets Direct

H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza). H5N1 Infection (Avian Influenza) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for H5N1 Infection (Avian Influenza).
- A review of READ MORE >

2
List of Tables 5
List of Figures 7
Introduction 8
REPORT COVERAGE 8
H5N1 Infection (Avian Influenza) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for H5N1 Infection (Avian Influenza) 10
H5N1 Infection (Avian Influenza) Therapeutics under Development by Companies 12
H5N1 Infection (Avian Influenza) Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
H5N1 Infection (Avian Influenza) Therapeutics – Products under Development by Companies 22
H5N1 Infection (Avian Influenza) Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in H5N1 Infection (Avian Influenza) Therapeutics Development 27
Baxter International Inc. 27
Sanofi-Aventis 28
GlaxoSmithKline plc 29
Inovio Biomedical Corporation 30
Emergent BioSolutions Inc. 31
Generex Biotechnology Corporation 32
Nanotherapeutics, Inc. 33
Archimedes Pharma Limited 34
Novartis AG 35
MDRNA, Inc. 36
Novavax, Inc. 37
CEL-SCI Corporation 38
Crucell N.V. 39
OPKO Health, Inc. 40
Hemispherx Biopharma, Inc. 41
Intercell AG 42
Medicago Inc. 43
NanoViricides, Inc. 44
CytoGenix, Inc. 45
XOMA Ltd. 46
Green Cross Corporation 47
Antigen Express, Inc. 48
Colby Pharmaceutical Company 49
LigoCyte Pharmaceuticals, Inc. 50
Adimmune Corporation 51
TechnoVax, Inc. 52
MacroGenics, Inc. 53
AlphaVax, Inc. 54
Vaxin, Inc. 55
Theraclone Sciences, Inc. 56
REPLICor Inc. 57
Protein Sciences Corporation 58
VaxInnate Corporation 59
Obio Pharmaceutical Holdings Limited. 60
Canopus BioPharma Incorporated 61
iBio, Inc. 62
Sirnaomics, Inc. 63
Alios BioPharma, Inc. 64
Vaxart, Inc. 65
NasVax Ltd. 66
The National Institute of Allergy and Infectious Diseases 67
ImmuneRegen BioSciences, Inc. 68
Inviragen, Inc. 69
PaxVax 70
Denka Seiken Co., Ltd. 71
H5N1 Infection (Avian Influenza) – Therapeutics Assessment 72
Assessment by Monotherapy Products 72
Assessment by Combination Products 73
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 79
H5N1 VLP Influenza Vaccine - Drug Profile 79
CR-6261 - Drug Profile 80
Homspera - Drug Profile 82
Flu Vaccine - Drug Profile 84
GelVac - Drug Profile 85
CEL-1000 - Drug Profile 86
VGX-3400X - Drug Profile 89
Alferon N Injection + Alferon LDO - Drug Profile 90
Pandemic Influenza Vaccine Patch - Drug Profile 91
REP-9AC - Drug Profile 93
H5N1 Vaccine - Drug Profile 95
Vaccine For Pandemic Influenza (H1 & H5) - Drug Profile 97
MDR-03030 - Drug Profile 98
PanBlok - Drug Profile 99
PanBlok - Drug Profile 101
TG-21 - Drug Profile 103
Vepacel - Drug Profile 104
Influenza Vaccine - Drug Profile 106
Aflunov - Drug Profile 108
H5N1 FCC Vaccine - Drug Profile 110
GSK-2340273-A - Drug Profile 111
STP-702 - Drug Profile 113
VRC-AVIDNA036-00-VP - Drug Profile 114
F-10 Antibody Program - Drug Profile 116
TVX-003 - Drug Profile 117
CYDBA-507 - Drug Profile 118
A/Indonesia/05/2005 + VRC-AViDNA036-00-VP - Drug Profile 119
VRC-AVIDNA036-00-VP + Monovalent Influenza Subunit Virion Vaccine - Drug Profile 120
Inactivated Influenza A/H5N1 Vaccine - Drug Profile 122
GSK-1557484-A - Drug Profile 123
Zofroxia - Drug Profile 125
Influenza VLP vaccine - Drug Profile 126
MVA-H5HA - Drug Profile 127
Avian Influenza (H5N1) Oral Vaccine - Drug Profile 128
Mult. mAbs/DARTs - Drug Profile 130
FhCMB HAI-05 - Drug Profile 131
Naspanvac - Drug Profile 132
A-04-01D Vaccine - Drug Profile 134
AE-AI Vaccine - Drug Profile 135
Monovalent Subvirion H5N1 Influenza Vaccine - Drug Profile 136
GSK-2590066-A - Drug Profile 138
Pandemic Influenza Program - Drug Profile 139
Flufirvitide-3 - Drug Profile 140
Anti-H5HA mAB - Drug Profile 141
H5N1 Avian Influenza Vaccine - Drug Profile 142
JVRS-100 + Pandemic Flu Vaccine - Drug Profile 144
Influenza A/H5N1 Virus Vaccine + AS03 - Drug Profile 146
PXVX-0103 - Drug Profile 147
TCN-032 - Drug Profile 148
MG-1109 - Drug Profile 150
INO-3510 - Drug Profile 151
INO-3401 - Drug Profile 152
AE-443p - Drug Profile 154
INO-3605 - Drug Profile 155
INO-3609 - Drug Profile 157
INO-3605 + INO-3609 - Drug Profile 159
NV-INF-1 - Drug Profile 161
Avian Influenza Vaccine - Drug Profile 162
VAX161 - Drug Profile 163
H1N1 Syncon Universal Influenza Vaccine - Drug Profile 164
AdimFlu-W - Drug Profile 165
H5N1 Avian Influenza VLP vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 166
VAX161-01C - Drug Profile 168
Nucleozin - Drug Profile 169
Inactivated Influenza H5N1 Vaccine - Drug Profile 170
AD4-H5-VTN Vaccine - Drug Profile 171
H5N1 Project - Drug Profile 172
H5N1 Infection (Avian Influenza) Therapeutics – Drug Profile Updates 173
H5N1 Infection (Avian Influenza) Therapeutics – Discontinued Products 186
H5N1 Infection (Avian Influenza) Therapeutics - Dormant Products 187
H5N1 Infection (Avian Influenza) – Product Development Milestones 189
Featured News & Press Releases 189
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 199
Disclaimer 199

List of Tables
Number of Products Under Development for H5N1 Infection (Avian Influenza), H2 2012 15
Products under Development for H5N1 Infection (Avian Influenza) – Comparative Analysis, H2 2012 16
Number of Products under Development by Companies, H2 2012 18
Number of Products under Development by Companies, H2 2012 (Contd..1) 19
Number of Products under Development by Companies, H2 2012 (Contd..2) 20
Number of Products under Development by Companies, H2 2012 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Comparative Analysis by Late Stage Development, H2 2012 23
Comparative Analysis by Mid Clinical Stage Development, H2 2012 24
Comparative Analysis by Early Clinical Stage Development, H2 2012 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Development by Companies, H2 2012 (Contd..1) 28
Products under Development by Companies, H2 2012 (Contd..2) 29
Products under Development by Companies, H2 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Baxter International Inc., H2 2012 32
Sanofi-Aventis, H2 2012 33
GlaxoSmithKline plc, H2 2012 34
Inovio Biomedical Corporation, H2 2012 35
Emergent BioSolutions Inc., H2 2012 36
Generex Biotechnology Corporation, H2 2012 37
Nanotherapeutics, Inc., H2 2012 38
Archimedes Pharma Limited, H2 2012 39
Novartis AG, H2 2012 40
MDRNA, Inc., H2 2012 41
Novavax, Inc., H2 2012 42
CEL-SCI Corporation, H2 2012 43
Crucell N.V., H2 2012 44
OPKO Health, Inc., H2 2012 45
Hemispherx Biopharma, Inc., H2 2012 46
Intercell AG, H2 2012 47
Medicago Inc., H2 2012 48
NanoViricides, Inc., H2 2012 49
CytoGenix, Inc., H2 2012 50
XOMA Ltd., H2 2012 51
Green Cross Corporation, H2 2012 52
Antigen Express, Inc., H2 2012 53
Colby Pharmaceutical Company, H2 2012 54
LigoCyte Pharmaceuticals, Inc., H2 2012 55
Adimmune Corporation, H2 2012 56
TechnoVax, Inc., H2 2012 57
MacroGenics, Inc., H2 2012 58
AlphaVax, Inc., H2 2012 59
Vaxin, Inc., H2 2012 60
Theraclone Sciences, Inc., H2 2012 61
REPLICor Inc., H2 2012 62
Protein Sciences Corporation, H2 2012 63
VaxInnate Corporation, H2 2012 64
Obio Pharmaceutical Holdings Limited., H2 2012 65
Canopus BioPharma Incorporated, H2 2012 66
iBio, Inc., H2 2012 67
Sirnaomics, Inc., H2 2012 68
Alios BioPharma, Inc., H2 2012 69
Vaxart, Inc., H2 2012 70
NasVax Ltd., H2 2012 71
The National Institute of Allergy and Infectious Diseases, H2 2012 72
ImmuneRegen BioSciences, Inc., H2 2012 73
Inviragen, Inc., H2 2012 74
PaxVax, H2 2012 75
Denka Seiken Co., Ltd., H2 2012 76
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Stage and Molecule Type, H2 2012 83
H5N1 Infection (Avian Influenza) Therapeutics – Drug Profile Updates 178
H5N1 Infection (Avian Influenza) Therapeutics – Discontinued Products 191
H5N1 Infection (Avian Influenza) Therapeutics – Dormant Products 192
H5N1 Infection (Avian Influenza) Therapeutics – Dormant Products (Contd..1) 193

List of Figures
Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2012 15
Products under Development for H5N1 Infection (Avian Influenza) – Comparative Analysis, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 23
Mid Clinical Stage Products, H2 2012 24
Early Clinical Stage Products, H2 2012 25
Discovery and Pre-Clinical Stage Products, H2 2012 26
Assessment by Monotherapy Products, H2 2012 77
Assessment by Combination Products, H2 2012 78
Assessment by Route of Administration, H2 2012 79
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Molecule Type, H2 2012 81
Assessment by Stage and Molecule Type, H2 2012 82

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos